A revised Ryan White bill clears Senate panel unanimously. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

A revised Ryan White bill clears Senate panel unanimously. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

AIDS Policy Law. 1995 Apr 21;10(7):1, 8-9. Unique Identifier : AIDSLINE AIDS/95700415

Abstract: The Senate Labor and Human Resources Committee gave unanimous support to Senate Bill 641, legislation to reauthorize the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act, before adjourning for the Easter recess. Assuming passage of the bill, the measure would then go to the House of Representatives. The new legislation would reauthorize the Ryan White CARE Act for the next five years. Funds would be distributed to emphasize recent AIDS caseloads. The Title II formula for states would be adjusted to prevent double-counting. Title I cities would be assured of receiving no less than 92.5 percent of their fiscal 1995 allocations. The Special Projects of National Significance (SPNS) program would be moved to a new Title V and funded by a three percent set-aside from each of the other four titles. Native American communities would be added to the list of eligible entities. A statewide planning process would be created to improve coordination among Title I cities and Title II states. Administrative expense caps for Titles I and II would be extended to subcontractors. Representation on Title I planning councils would be changed to more accurately reflect the demographics of the epidemic in each city. Co-morbidity conditions, such as tuberculosis, would be given higher priority in Title I supplemental grants to reflect a greater need for care. Although advocacy groups are encouraged by the legislation, concern arises regarding how much funding the CARE program will receive.

Keywords: *Acquired Immunodeficiency Syndrome Capital Financing Financing, Government *Politics United States NEWSLETTER ARTICLE
951230
M95C3185

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .